0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Genetic Testing for Cancer Risk Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-13M14043
Home | Market Reports | Science| Biological Sciences
Global Genetic Testing for Cancer Risk Market Research Report 2023
BUY CHAPTERS

Global Genetic Testing for Cancer Risk Market Research Report 2025

Code: QYRE-Auto-13M14043
Report
May 2025
Pages:104
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Genetic Testing for Cancer Risk Market Size

The global market for Genetic Testing for Cancer Risk was valued at US$ 5281 million in the year 2024 and is projected to reach a revised size of US$ 11760 million by 2031, growing at a CAGR of 12.3% during the forecast period.

Genetic Testing for Cancer Risk Market

Genetic Testing for Cancer Risk Market

Cancer risk genetic testing looks for changes in someone"s genes. Genetic changes can cause some cancers. Some cancers can run in families.
The demand for genetic testing for cancer risk has been increasing in recent years due to the growing understanding of the role of genetics in cancer development and the desire for personalized healthcare. Genetic tests can provide valuable information for individuals and healthcare professionals, allowing for early detection, prevention, and personalized treatment strategies.
This report aims to provide a comprehensive presentation of the global market for Genetic Testing for Cancer Risk, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Genetic Testing for Cancer Risk.
The Genetic Testing for Cancer Risk market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Genetic Testing for Cancer Risk market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Genetic Testing for Cancer Risk companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Genetic Testing for Cancer Risk Market Report

Report Metric Details
Report Name Genetic Testing for Cancer Risk Market
Accounted market size in year US$ 5281 million
Forecasted market size in 2031 US$ 11760 million
CAGR 12.3%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Hospital
  • Clinic
  • Laboratory
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Myriad Genetics, Inc., Invitae Corporation, Illumina, Inc., Natera, Inc., Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, CooperSurgical, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Twist Bioscience, Sophia Genetics, Fulgent Genetic, Inc., Medgenome, CENTOGENE, CeGaT, LifeLabs Genetics, Ambry Genetics, BGI, SOFIVA GENOMICS, Yikon Medical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Genetic Testing for Cancer Risk company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Genetic Testing for Cancer Risk Market growing?

Ans: The Genetic Testing for Cancer Risk Market witnessing a CAGR of 12.3% during the forecast period 2025-2031.

What is the Genetic Testing for Cancer Risk Market size in 2031?

Ans: The Genetic Testing for Cancer Risk Market size in 2031 will be US$ 11760 million.

Who are the main players in the Genetic Testing for Cancer Risk Market report?

Ans: The main players in the Genetic Testing for Cancer Risk Market are Myriad Genetics, Inc., Invitae Corporation, Illumina, Inc., Natera, Inc., Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, CooperSurgical, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Twist Bioscience, Sophia Genetics, Fulgent Genetic, Inc., Medgenome, CENTOGENE, CeGaT, LifeLabs Genetics, Ambry Genetics, BGI, SOFIVA GENOMICS, Yikon Medical

What are the Application segmentation covered in the Genetic Testing for Cancer Risk Market report?

Ans: The Applications covered in the Genetic Testing for Cancer Risk Market report are Hospital, Clinic, Laboratory

What are the Type segmentation covered in the Genetic Testing for Cancer Risk Market report?

Ans: The Types covered in the Genetic Testing for Cancer Risk Market report are Breast Cancer Risk Genetic Testing, Stomach Cancer Risk Gene Testing, Rectal Cancer Risk Genetic Testing, Others

Recommended Reports

Cancer Genetic Testing

Hereditary Disease Testing

Genotype and Genome Testing

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Genetic Testing for Cancer Risk Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Breast Cancer Risk Genetic Testing
1.2.3 Stomach Cancer Risk Gene Testing
1.2.4 Rectal Cancer Risk Genetic Testing
1.2.5 Others
1.3 Market by Application
1.3.1 Global Genetic Testing for Cancer Risk Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Laboratory
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Genetic Testing for Cancer Risk Market Perspective (2020-2031)
2.2 Global Genetic Testing for Cancer Risk Growth Trends by Region
2.2.1 Global Genetic Testing for Cancer Risk Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Genetic Testing for Cancer Risk Historic Market Size by Region (2020-2025)
2.2.3 Genetic Testing for Cancer Risk Forecasted Market Size by Region (2026-2031)
2.3 Genetic Testing for Cancer Risk Market Dynamics
2.3.1 Genetic Testing for Cancer Risk Industry Trends
2.3.2 Genetic Testing for Cancer Risk Market Drivers
2.3.3 Genetic Testing for Cancer Risk Market Challenges
2.3.4 Genetic Testing for Cancer Risk Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Genetic Testing for Cancer Risk Players by Revenue
3.1.1 Global Top Genetic Testing for Cancer Risk Players by Revenue (2020-2025)
3.1.2 Global Genetic Testing for Cancer Risk Revenue Market Share by Players (2020-2025)
3.2 Global Genetic Testing for Cancer Risk Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Genetic Testing for Cancer Risk Revenue
3.4 Global Genetic Testing for Cancer Risk Market Concentration Ratio
3.4.1 Global Genetic Testing for Cancer Risk Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Genetic Testing for Cancer Risk Revenue in 2024
3.5 Global Key Players of Genetic Testing for Cancer Risk Head office and Area Served
3.6 Global Key Players of Genetic Testing for Cancer Risk, Product and Application
3.7 Global Key Players of Genetic Testing for Cancer Risk, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Genetic Testing for Cancer Risk Breakdown Data by Type
4.1 Global Genetic Testing for Cancer Risk Historic Market Size by Type (2020-2025)
4.2 Global Genetic Testing for Cancer Risk Forecasted Market Size by Type (2026-2031)
5 Genetic Testing for Cancer Risk Breakdown Data by Application
5.1 Global Genetic Testing for Cancer Risk Historic Market Size by Application (2020-2025)
5.2 Global Genetic Testing for Cancer Risk Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Genetic Testing for Cancer Risk Market Size (2020-2031)
6.2 North America Genetic Testing for Cancer Risk Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Genetic Testing for Cancer Risk Market Size by Country (2020-2025)
6.4 North America Genetic Testing for Cancer Risk Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Genetic Testing for Cancer Risk Market Size (2020-2031)
7.2 Europe Genetic Testing for Cancer Risk Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Genetic Testing for Cancer Risk Market Size by Country (2020-2025)
7.4 Europe Genetic Testing for Cancer Risk Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Genetic Testing for Cancer Risk Market Size (2020-2031)
8.2 Asia-Pacific Genetic Testing for Cancer Risk Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Genetic Testing for Cancer Risk Market Size by Region (2020-2025)
8.4 Asia-Pacific Genetic Testing for Cancer Risk Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Genetic Testing for Cancer Risk Market Size (2020-2031)
9.2 Latin America Genetic Testing for Cancer Risk Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Genetic Testing for Cancer Risk Market Size by Country (2020-2025)
9.4 Latin America Genetic Testing for Cancer Risk Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Genetic Testing for Cancer Risk Market Size (2020-2031)
10.2 Middle East & Africa Genetic Testing for Cancer Risk Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Genetic Testing for Cancer Risk Market Size by Country (2020-2025)
10.4 Middle East & Africa Genetic Testing for Cancer Risk Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Myriad Genetics, Inc.
11.1.1 Myriad Genetics, Inc. Company Details
11.1.2 Myriad Genetics, Inc. Business Overview
11.1.3 Myriad Genetics, Inc. Genetic Testing for Cancer Risk Introduction
11.1.4 Myriad Genetics, Inc. Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.1.5 Myriad Genetics, Inc. Recent Development
11.2 Invitae Corporation
11.2.1 Invitae Corporation Company Details
11.2.2 Invitae Corporation Business Overview
11.2.3 Invitae Corporation Genetic Testing for Cancer Risk Introduction
11.2.4 Invitae Corporation Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.2.5 Invitae Corporation Recent Development
11.3 Illumina, Inc.
11.3.1 Illumina, Inc. Company Details
11.3.2 Illumina, Inc. Business Overview
11.3.3 Illumina, Inc. Genetic Testing for Cancer Risk Introduction
11.3.4 Illumina, Inc. Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.3.5 Illumina, Inc. Recent Development
11.4 Natera, Inc.
11.4.1 Natera, Inc. Company Details
11.4.2 Natera, Inc. Business Overview
11.4.3 Natera, Inc. Genetic Testing for Cancer Risk Introduction
11.4.4 Natera, Inc. Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.4.5 Natera, Inc. Recent Development
11.5 Laboratory Corporation of America Holdings
11.5.1 Laboratory Corporation of America Holdings Company Details
11.5.2 Laboratory Corporation of America Holdings Business Overview
11.5.3 Laboratory Corporation of America Holdings Genetic Testing for Cancer Risk Introduction
11.5.4 Laboratory Corporation of America Holdings Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.5.5 Laboratory Corporation of America Holdings Recent Development
11.6 F. Hoffmann-La Roche Ltd
11.6.1 F. Hoffmann-La Roche Ltd Company Details
11.6.2 F. Hoffmann-La Roche Ltd Business Overview
11.6.3 F. Hoffmann-La Roche Ltd Genetic Testing for Cancer Risk Introduction
11.6.4 F. Hoffmann-La Roche Ltd Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.6.5 F. Hoffmann-La Roche Ltd Recent Development
11.7 Quest Diagnostics Incorporated
11.7.1 Quest Diagnostics Incorporated Company Details
11.7.2 Quest Diagnostics Incorporated Business Overview
11.7.3 Quest Diagnostics Incorporated Genetic Testing for Cancer Risk Introduction
11.7.4 Quest Diagnostics Incorporated Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.7.5 Quest Diagnostics Incorporated Recent Development
11.8 CooperSurgical, Inc.
11.8.1 CooperSurgical, Inc. Company Details
11.8.2 CooperSurgical, Inc. Business Overview
11.8.3 CooperSurgical, Inc. Genetic Testing for Cancer Risk Introduction
11.8.4 CooperSurgical, Inc. Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.8.5 CooperSurgical, Inc. Recent Development
11.9 Agilent Technologies, Inc.
11.9.1 Agilent Technologies, Inc. Company Details
11.9.2 Agilent Technologies, Inc. Business Overview
11.9.3 Agilent Technologies, Inc. Genetic Testing for Cancer Risk Introduction
11.9.4 Agilent Technologies, Inc. Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.9.5 Agilent Technologies, Inc. Recent Development
11.10 Thermo Fisher Scientific, Inc.
11.10.1 Thermo Fisher Scientific, Inc. Company Details
11.10.2 Thermo Fisher Scientific, Inc. Business Overview
11.10.3 Thermo Fisher Scientific, Inc. Genetic Testing for Cancer Risk Introduction
11.10.4 Thermo Fisher Scientific, Inc. Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.10.5 Thermo Fisher Scientific, Inc. Recent Development
11.11 Twist Bioscience
11.11.1 Twist Bioscience Company Details
11.11.2 Twist Bioscience Business Overview
11.11.3 Twist Bioscience Genetic Testing for Cancer Risk Introduction
11.11.4 Twist Bioscience Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.11.5 Twist Bioscience Recent Development
11.12 Sophia Genetics
11.12.1 Sophia Genetics Company Details
11.12.2 Sophia Genetics Business Overview
11.12.3 Sophia Genetics Genetic Testing for Cancer Risk Introduction
11.12.4 Sophia Genetics Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.12.5 Sophia Genetics Recent Development
11.13 Fulgent Genetic, Inc.
11.13.1 Fulgent Genetic, Inc. Company Details
11.13.2 Fulgent Genetic, Inc. Business Overview
11.13.3 Fulgent Genetic, Inc. Genetic Testing for Cancer Risk Introduction
11.13.4 Fulgent Genetic, Inc. Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.13.5 Fulgent Genetic, Inc. Recent Development
11.14 Medgenome
11.14.1 Medgenome Company Details
11.14.2 Medgenome Business Overview
11.14.3 Medgenome Genetic Testing for Cancer Risk Introduction
11.14.4 Medgenome Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.14.5 Medgenome Recent Development
11.15 CENTOGENE
11.15.1 CENTOGENE Company Details
11.15.2 CENTOGENE Business Overview
11.15.3 CENTOGENE Genetic Testing for Cancer Risk Introduction
11.15.4 CENTOGENE Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.15.5 CENTOGENE Recent Development
11.16 CeGaT
11.16.1 CeGaT Company Details
11.16.2 CeGaT Business Overview
11.16.3 CeGaT Genetic Testing for Cancer Risk Introduction
11.16.4 CeGaT Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.16.5 CeGaT Recent Development
11.17 LifeLabs Genetics
11.17.1 LifeLabs Genetics Company Details
11.17.2 LifeLabs Genetics Business Overview
11.17.3 LifeLabs Genetics Genetic Testing for Cancer Risk Introduction
11.17.4 LifeLabs Genetics Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.17.5 LifeLabs Genetics Recent Development
11.18 Ambry Genetics
11.18.1 Ambry Genetics Company Details
11.18.2 Ambry Genetics Business Overview
11.18.3 Ambry Genetics Genetic Testing for Cancer Risk Introduction
11.18.4 Ambry Genetics Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.18.5 Ambry Genetics Recent Development
11.19 BGI
11.19.1 BGI Company Details
11.19.2 BGI Business Overview
11.19.3 BGI Genetic Testing for Cancer Risk Introduction
11.19.4 BGI Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.19.5 BGI Recent Development
11.20 SOFIVA GENOMICS
11.20.1 SOFIVA GENOMICS Company Details
11.20.2 SOFIVA GENOMICS Business Overview
11.20.3 SOFIVA GENOMICS Genetic Testing for Cancer Risk Introduction
11.20.4 SOFIVA GENOMICS Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.20.5 SOFIVA GENOMICS Recent Development
11.21 Yikon Medical
11.21.1 Yikon Medical Company Details
11.21.2 Yikon Medical Business Overview
11.21.3 Yikon Medical Genetic Testing for Cancer Risk Introduction
11.21.4 Yikon Medical Revenue in Genetic Testing for Cancer Risk Business (2020-2025)
11.21.5 Yikon Medical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Genetic Testing for Cancer Risk Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Breast Cancer Risk Genetic Testing
 Table 3. Key Players of Stomach Cancer Risk Gene Testing
 Table 4. Key Players of Rectal Cancer Risk Genetic Testing
 Table 5. Key Players of Others
 Table 6. Global Genetic Testing for Cancer Risk Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Genetic Testing for Cancer Risk Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Genetic Testing for Cancer Risk Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global Genetic Testing for Cancer Risk Market Share by Region (2020-2025)
 Table 10. Global Genetic Testing for Cancer Risk Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global Genetic Testing for Cancer Risk Market Share by Region (2026-2031)
 Table 12. Genetic Testing for Cancer Risk Market Trends
 Table 13. Genetic Testing for Cancer Risk Market Drivers
 Table 14. Genetic Testing for Cancer Risk Market Challenges
 Table 15. Genetic Testing for Cancer Risk Market Restraints
 Table 16. Global Genetic Testing for Cancer Risk Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global Genetic Testing for Cancer Risk Market Share by Players (2020-2025)
 Table 18. Global Top Genetic Testing for Cancer Risk Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Genetic Testing for Cancer Risk as of 2024)
 Table 19. Ranking of Global Top Genetic Testing for Cancer Risk Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by Genetic Testing for Cancer Risk Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of Genetic Testing for Cancer Risk, Headquarters and Area Served
 Table 22. Global Key Players of Genetic Testing for Cancer Risk, Product and Application
 Table 23. Global Key Players of Genetic Testing for Cancer Risk, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Genetic Testing for Cancer Risk Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global Genetic Testing for Cancer Risk Revenue Market Share by Type (2020-2025)
 Table 27. Global Genetic Testing for Cancer Risk Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global Genetic Testing for Cancer Risk Revenue Market Share by Type (2026-2031)
 Table 29. Global Genetic Testing for Cancer Risk Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global Genetic Testing for Cancer Risk Revenue Market Share by Application (2020-2025)
 Table 31. Global Genetic Testing for Cancer Risk Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global Genetic Testing for Cancer Risk Revenue Market Share by Application (2026-2031)
 Table 33. North America Genetic Testing for Cancer Risk Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America Genetic Testing for Cancer Risk Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America Genetic Testing for Cancer Risk Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe Genetic Testing for Cancer Risk Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe Genetic Testing for Cancer Risk Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe Genetic Testing for Cancer Risk Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific Genetic Testing for Cancer Risk Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific Genetic Testing for Cancer Risk Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific Genetic Testing for Cancer Risk Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Genetic Testing for Cancer Risk Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America Genetic Testing for Cancer Risk Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Genetic Testing for Cancer Risk Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa Genetic Testing for Cancer Risk Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa Genetic Testing for Cancer Risk Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa Genetic Testing for Cancer Risk Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Myriad Genetics, Inc. Company Details
 Table 49. Myriad Genetics, Inc. Business Overview
 Table 50. Myriad Genetics, Inc. Genetic Testing for Cancer Risk Product
 Table 51. Myriad Genetics, Inc. Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 52. Myriad Genetics, Inc. Recent Development
 Table 53. Invitae Corporation Company Details
 Table 54. Invitae Corporation Business Overview
 Table 55. Invitae Corporation Genetic Testing for Cancer Risk Product
 Table 56. Invitae Corporation Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 57. Invitae Corporation Recent Development
 Table 58. Illumina, Inc. Company Details
 Table 59. Illumina, Inc. Business Overview
 Table 60. Illumina, Inc. Genetic Testing for Cancer Risk Product
 Table 61. Illumina, Inc. Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 62. Illumina, Inc. Recent Development
 Table 63. Natera, Inc. Company Details
 Table 64. Natera, Inc. Business Overview
 Table 65. Natera, Inc. Genetic Testing for Cancer Risk Product
 Table 66. Natera, Inc. Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 67. Natera, Inc. Recent Development
 Table 68. Laboratory Corporation of America Holdings Company Details
 Table 69. Laboratory Corporation of America Holdings Business Overview
 Table 70. Laboratory Corporation of America Holdings Genetic Testing for Cancer Risk Product
 Table 71. Laboratory Corporation of America Holdings Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 72. Laboratory Corporation of America Holdings Recent Development
 Table 73. F. Hoffmann-La Roche Ltd Company Details
 Table 74. F. Hoffmann-La Roche Ltd Business Overview
 Table 75. F. Hoffmann-La Roche Ltd Genetic Testing for Cancer Risk Product
 Table 76. F. Hoffmann-La Roche Ltd Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 77. F. Hoffmann-La Roche Ltd Recent Development
 Table 78. Quest Diagnostics Incorporated Company Details
 Table 79. Quest Diagnostics Incorporated Business Overview
 Table 80. Quest Diagnostics Incorporated Genetic Testing for Cancer Risk Product
 Table 81. Quest Diagnostics Incorporated Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 82. Quest Diagnostics Incorporated Recent Development
 Table 83. CooperSurgical, Inc. Company Details
 Table 84. CooperSurgical, Inc. Business Overview
 Table 85. CooperSurgical, Inc. Genetic Testing for Cancer Risk Product
 Table 86. CooperSurgical, Inc. Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 87. CooperSurgical, Inc. Recent Development
 Table 88. Agilent Technologies, Inc. Company Details
 Table 89. Agilent Technologies, Inc. Business Overview
 Table 90. Agilent Technologies, Inc. Genetic Testing for Cancer Risk Product
 Table 91. Agilent Technologies, Inc. Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 92. Agilent Technologies, Inc. Recent Development
 Table 93. Thermo Fisher Scientific, Inc. Company Details
 Table 94. Thermo Fisher Scientific, Inc. Business Overview
 Table 95. Thermo Fisher Scientific, Inc. Genetic Testing for Cancer Risk Product
 Table 96. Thermo Fisher Scientific, Inc. Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 97. Thermo Fisher Scientific, Inc. Recent Development
 Table 98. Twist Bioscience Company Details
 Table 99. Twist Bioscience Business Overview
 Table 100. Twist Bioscience Genetic Testing for Cancer Risk Product
 Table 101. Twist Bioscience Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 102. Twist Bioscience Recent Development
 Table 103. Sophia Genetics Company Details
 Table 104. Sophia Genetics Business Overview
 Table 105. Sophia Genetics Genetic Testing for Cancer Risk Product
 Table 106. Sophia Genetics Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 107. Sophia Genetics Recent Development
 Table 108. Fulgent Genetic, Inc. Company Details
 Table 109. Fulgent Genetic, Inc. Business Overview
 Table 110. Fulgent Genetic, Inc. Genetic Testing for Cancer Risk Product
 Table 111. Fulgent Genetic, Inc. Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 112. Fulgent Genetic, Inc. Recent Development
 Table 113. Medgenome Company Details
 Table 114. Medgenome Business Overview
 Table 115. Medgenome Genetic Testing for Cancer Risk Product
 Table 116. Medgenome Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 117. Medgenome Recent Development
 Table 118. CENTOGENE Company Details
 Table 119. CENTOGENE Business Overview
 Table 120. CENTOGENE Genetic Testing for Cancer Risk Product
 Table 121. CENTOGENE Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 122. CENTOGENE Recent Development
 Table 123. CeGaT Company Details
 Table 124. CeGaT Business Overview
 Table 125. CeGaT Genetic Testing for Cancer Risk Product
 Table 126. CeGaT Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 127. CeGaT Recent Development
 Table 128. LifeLabs Genetics Company Details
 Table 129. LifeLabs Genetics Business Overview
 Table 130. LifeLabs Genetics Genetic Testing for Cancer Risk Product
 Table 131. LifeLabs Genetics Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 132. LifeLabs Genetics Recent Development
 Table 133. Ambry Genetics Company Details
 Table 134. Ambry Genetics Business Overview
 Table 135. Ambry Genetics Genetic Testing for Cancer Risk Product
 Table 136. Ambry Genetics Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 137. Ambry Genetics Recent Development
 Table 138. BGI Company Details
 Table 139. BGI Business Overview
 Table 140. BGI Genetic Testing for Cancer Risk Product
 Table 141. BGI Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 142. BGI Recent Development
 Table 143. SOFIVA GENOMICS Company Details
 Table 144. SOFIVA GENOMICS Business Overview
 Table 145. SOFIVA GENOMICS Genetic Testing for Cancer Risk Product
 Table 146. SOFIVA GENOMICS Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 147. SOFIVA GENOMICS Recent Development
 Table 148. Yikon Medical Company Details
 Table 149. Yikon Medical Business Overview
 Table 150. Yikon Medical Genetic Testing for Cancer Risk Product
 Table 151. Yikon Medical Revenue in Genetic Testing for Cancer Risk Business (2020-2025) & (US$ Million)
 Table 152. Yikon Medical Recent Development
 Table 153. Research Programs/Design for This Report
 Table 154. Key Data Information from Secondary Sources
 Table 155. Key Data Information from Primary Sources
 Table 156. Authors List of This Report


List of Figures
 Figure 1. Genetic Testing for Cancer Risk Picture
 Figure 2. Global Genetic Testing for Cancer Risk Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Genetic Testing for Cancer Risk Market Share by Type: 2024 VS 2031
 Figure 4. Breast Cancer Risk Genetic Testing Features
 Figure 5. Stomach Cancer Risk Gene Testing Features
 Figure 6. Rectal Cancer Risk Genetic Testing Features
 Figure 7. Others Features
 Figure 8. Global Genetic Testing for Cancer Risk Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global Genetic Testing for Cancer Risk Market Share by Application: 2024 VS 2031
 Figure 10. Hospital Case Studies
 Figure 11. Clinic Case Studies
 Figure 12. Laboratory Case Studies
 Figure 13. Genetic Testing for Cancer Risk Report Years Considered
 Figure 14. Global Genetic Testing for Cancer Risk Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 15. Global Genetic Testing for Cancer Risk Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Genetic Testing for Cancer Risk Market Share by Region: 2024 VS 2031
 Figure 17. Global Genetic Testing for Cancer Risk Market Share by Players in 2024
 Figure 18. Global Top Genetic Testing for Cancer Risk Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Genetic Testing for Cancer Risk as of 2024)
 Figure 19. The Top 10 and 5 Players Market Share by Genetic Testing for Cancer Risk Revenue in 2024
 Figure 20. North America Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. North America Genetic Testing for Cancer Risk Market Share by Country (2020-2031)
 Figure 22. United States Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Canada Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Genetic Testing for Cancer Risk Market Share by Country (2020-2031)
 Figure 26. Germany Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Nordic Countries Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Genetic Testing for Cancer Risk Market Share by Region (2020-2031)
 Figure 34. China Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Japan Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. South Korea Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Southeast Asia Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. India Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Australia Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Genetic Testing for Cancer Risk Market Share by Country (2020-2031)
 Figure 42. Mexico Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Brazil Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Genetic Testing for Cancer Risk Market Share by Country (2020-2031)
 Figure 46. Turkey Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Saudi Arabia Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UAE Genetic Testing for Cancer Risk Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Myriad Genetics, Inc. Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 50. Invitae Corporation Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 51. Illumina, Inc. Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 52. Natera, Inc. Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 53. Laboratory Corporation of America Holdings Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 54. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 55. Quest Diagnostics Incorporated Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 56. CooperSurgical, Inc. Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 57. Agilent Technologies, Inc. Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 58. Thermo Fisher Scientific, Inc. Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 59. Twist Bioscience Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 60. Sophia Genetics Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 61. Fulgent Genetic, Inc. Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 62. Medgenome Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 63. CENTOGENE Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 64. CeGaT Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 65. LifeLabs Genetics Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 66. Ambry Genetics Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 67. BGI Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 68. SOFIVA GENOMICS Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 69. Yikon Medical Revenue Growth Rate in Genetic Testing for Cancer Risk Business (2020-2025)
 Figure 70. Bottom-up and Top-down Approaches for This Report
 Figure 71. Data Triangulation
 Figure 72. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS